Enveric Biosciences, Inc. (ENVB)
$1.40-4.76%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $835,817
- Beta
- 1.18
- P/E (TTM)
- -0.09
- Short % float
- 2.83%
- Days to cover
- 1.0
- SI change
- -32.5%
- 1W
- -4.76%
- 1M
- -5.41%
- vs SPY 1W
- -4.62%
- vs SPY 1M
- -7.91%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 9
- VALUE
- 17
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-100.8%
REV YoY-
ROE-168.1%
EPS YoY-
ROA-97.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.09
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.69
P/FCF-
EV/EBITDA0.24
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO10.21
ND/EBITDA-
BETA1.18
Company news
FAQ
- What is LOPJLB’s current signal on ENVB?
- LOPJLB’s latest quantitative signal on Enveric Biosciences, Inc. (ENVB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ENVB in?
- Enveric Biosciences, Inc. (ENVB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Enveric Biosciences, Inc. (ENVB) do?
- Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alo…